A2A Pharmaceuticals, Inc. Announces Phase 1 Clinical Trial Advancements in TACC3 Inhibition Program Targeting Multiple Cancers ...Middle East

NEW YORK, Dec. 11, 2024 /PRNewswire/ -- A2A Pharmaceuticals, Inc. ("A2A or "the company"), a clinical-stage pioneering biopharmaceutical company focused on developing innovative cancer therapies, today announced significant progress in its clinical studies exploring TACC3 (Transforming...

Hence then, the article about a2a pharmaceuticals inc announces phase 1 clinical trial advancements in tacc3 inhibition program targeting multiple cancers was published today ( Thursday 12/12/2024 - 03:01 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( A2A Pharmaceuticals, Inc. Announces Phase 1 Clinical Trial Advancements in TACC3 Inhibition Program Targeting Multiple Cancers )

Also on site :

• 1971 Folk Classic, by 'Genius' Singer-Songwriter, Helped Define One of the 'Best Movies of the 21st Century'
• Twins To Recall Zebby Matthews
• US seeking to convince China to pressure Iran – Rubio